Sirio Pharma
Shantou, China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Sirio Pharma
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Shantou, China
- Modalities
- Softgels, Hard Capsules, Gummies, Tablets, Dietary Supplements, Functional Foods, Nutraceuticals, OTC Products
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Sirio Pharma
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSoftgels, Hard Capsules, Gummies, Tablets, Dietary Supplements, Functional Foods, Nutraceuticals, OTC Products
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (8 modalities)
Recent News 10 articles
SIRIO debuts Aeion longevity platform with eight ready-to-market supplement concepts at Vitafoods Europe - Nutraceutical Business Review
Sirio rides Southeast Asia’s nutraceutical boom with major Q4 expansion - Nutraceutical Business Review
Nutraceutical CDMO Sirio launches high-strength gummy technology, XtraGummies - Nutraceutical Business Review
Nutraceutical CDMO Sirio Pharma to build new $40m gummy production site in Thailand - Nutraceutical Business Review
Talking, tasting, innovating: SIRIO shares behind-the-scenes highlights from its innovation summit - Nutraceutical Business Review
Sirio Pharma gains production licence of sports nutrition food in China - Nutraceutical Business Review
CDMO Sirio Pharma Completes the Acquisition of Best Formulations - Contract Pharma
Sirio Pharma introduces plant-based nutraceutical CDMO services - Nutraceutical Business Review
Sirio Pharma announces agreement to acquire Best Formulations - Nutraceutical Business Review
Sirio Pharma appoints Mark Dewis as General Manager of Sirio Americas Business Unit - Nutraceutical Business Review
Frequently Asked Questions About Sirio Pharma
What is Sirio Pharma's CDMO Signal Score?
Sirio Pharma has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Sirio Pharma for a manufacturing program?
Use the free AI matchmaker to compare Sirio Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.